Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Statera BioPharma (STAB)
OTHER OTC:STAB
Holding STAB?
Track your performance easily
STAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range― - ―
Previous Close$0.01
Volume11.64K
Average Volume (3M)N/A
Market Cap
$7.14K
Enterprise Value$6.98M
Total Cash (Recent Filing)$506.10K
Total Debt (Recent Filing)$7.41M
Price to Earnings (P/E)―
Beta14943.06
Next Earnings
Aug 14, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding71,420,000
10 Day Avg. Volume24,498
30 Day Avg. VolumeN/A
Standard Deviation38.61
R-Squared0.04
Alpha3.28
Financial Highlights & Ratios
Price to Book (P/B)-0.00100
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.89
Enterprise Value/Gross Profit-14.29
Enterprise Value/Ebitda-0.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
STAB FAQ
What was Statera BioPharma’s price range in the past 12 months?
Currently, no data Available
What is Statera BioPharma’s market cap?
Currently, no data Available
When is Statera BioPharma’s upcoming earnings report date?
Statera BioPharma’s upcoming earnings report date is Aug 14, 2023 which is 466 days ago.
How were Statera BioPharma’s earnings last quarter?
Statera BioPharma released its earnings results on Nov 14, 2022. The company reported -$0.067 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.067.
Is Statera BioPharma overvalued?
According to Wall Street analysts Statera BioPharma’s price is currently Overvalued.
Does Statera BioPharma pay dividends?
Statera BioPharma does not currently pay dividends.
What is Statera BioPharma’s EPS estimate?
Statera BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Statera BioPharma have?
Statera BioPharma has 71,416,040 shares outstanding.
What happened to Statera BioPharma’s price movement after its last earnings report?
Statera BioPharma reported an EPS of -$0.067 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Statera BioPharma?
Currently, no hedge funds are holding shares in STAB
---
Company Description
Statera BioPharma
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.
---
---